MARKET WIREYahoo Finance UK • 19h ago
Moleculin Biotech, Inc. (MBRX) stock price, news, quote and historyYahoo Finance UK report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
Why MBRX Stock dropped -9.40% Today — RQD Quant Desk Flash
$7.90 -9.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.75
Moleculin Biotech Inc. (MBRX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $8.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MBRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Moleculin Biotech Inc. (NASDAQ: MBRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.90 (-9.40% 1D, market cap $8.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MBRX ranks #653 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MBRX compare to ENSC and CURX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENSC (Ensysce Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M). Among the 5-stock peer group, MBRX leads on earnings multiple (N/A) while MBRX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MBRX?
▼
Per MBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001659617), Moleculin Biotech Inc. generated $70.3M in revenue (-5.8% YoY), $33.6M in net income, and -$22.7M in free cash flow against $22.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.75 (-1.88%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY MBRX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 45.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$8.70-28.9% Next Q
42
Q2 (-2Q)Grade E$6.19+49.8% Next Q
39
Q3 (-1Q)Grade E$9.27-14.8% Next Q
37
CurrentGrade E$7.90-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MBRX Turnaround Squeeze
While MBRX currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.70) and Max Pain ($8.30) forces dealer call-delta covering toward $111.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MBRX Stock dropped -9.40% Today — RQD Quant Desk Flash
Moleculin Biotech Inc. (MBRX) dropped -9.40% to $7.90, trading at 5% of its 52-week range ($3.13 – $106). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($3.13 – $106) with RSI-14 at 45.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MBRX Headlines & Catalysts
MARKET WIRECNN • 22h ago
symbol__ Stock Quote Price and ForecastCNN report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Moleculin Biotech (MBRX) Announces 1-for-20 Reverse Stock Split Amid Market SelloffGuruFocus report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Moleculin Announces Reverse Stock SplitGlobeNewswire report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Half of the CFO's stock awards vest on grant at Moleculin Biotech (MBRX).Stock Titan report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Half of a 250,000-option grant vests on the grant date at Moleculin Biotech (MBRX).Stock Titan report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A p
RISK WATCHBenzinga • 4d ago
Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid LeukemiaMoleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination
MARKET WIREBenzinga • 6d ago
12 Health Care Stocks Moving In Tuesday's Intraday SessionGainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBRX)
- ✓Walkthrough of MBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.07%▲ RESISTANCE BREAKOUT
2026-11-03O $8.72H $8.72L $7.90C $7.90VOL 31.7K
RES: $7.25SUP: $4.66SMA50: $10.70SMA200: $39.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MBRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MBRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBRX)
Health Care Rank #653 of 1016
⚔️ ENSC vs MBRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MBRX vs. ENSC, CURX, TCRT, INM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Moleculin Biotech Inc. (MBRX) ranks #653 by composite RQD confidence (34/100, grade E) and #908 by equity capitalization ($8.3M). Within this direct 5-issuer industry benchmark cohort, MBRX leads on earnings valuation at N/A trailing P/E, while MBRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBRX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MBRX
ACTIVE
Moleculin Biotech Inc. | E | 34/100 | — | — | -35.0% | -9.40% | $8.3M | Benchmark Subject |
| ENSC Ensysce Biosciences Inc. | E | 30/100 | — | — | -35.0% | -3.88% | $8.2M | /ensc-vs-mbrx → |
| CURX Curanex Pharmaceuticals Inc | D- | 37/100 | — | — | -35.0% | +4.45% | $8.1M | /curx-vs-mbrx → |
| TCRT Alaunos Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +3.18% | $8.1M | /tcrt-vs-mbrx → |
| INM InMed Pharmaceuticals Inc. | D | 47/100 | — | 34.5% | -35.0% | -1.54% | $8.8M | /inm-vs-mbrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001659617In its most recent audited fiscal period (FY2025, filed 2025-12-31), Moleculin Biotech Inc. (MBRX) reported GAAP revenue of $70.3M (-5.8% vs. FY2024 revenue of $74.6M , and -15.3% cumulative change since FY2023) , GAAP net income of $33.6M, operating cash flow of -$22.7M, and free cash flow of -$22.7M (+4.8% YoY). On the balance sheet, MBRX closed FY2025 with $22.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $70.3M | $33.6M | -$22.7M | -$22.7M | $22.1M | — |
| FY2024 (FY) | 2024-12-31 | $74.6M | $26.0M | -$23.9M | -$23.9M | $16.9M | — |
| FY2023 (FY) | 2023-12-31 | $83.0M | $29.8M | -$23.6M | -$23.6M | — | — |
3. MBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Moleculin Biotech Inc. (NASDAQ: MBRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.90 (-9.40% 1D, market cap $8.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MBRX ranks #653 in composite RQD confidence.
How does MBRX compare to ENSC and CURX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENSC (Ensysce Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M). Among the 5-stock peer group, MBRX leads on earnings multiple (N/A) while MBRX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MBRX?
Per MBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001659617), Moleculin Biotech Inc. generated $70.3M in revenue (-5.8% YoY), $33.6M in net income, and -$22.7M in free cash flow against $22.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MBRX trading relative to its 50-day, 200-day, and 52-week technical levels?
MBRX last traded at $7.90 (-9.40% on volume of 31,742 shares), positioning the stock -26.17% below its 50-day simple moving average ($10.70) and -80.07% below its 200-day simple moving average ($39.63). Across its 52-week range of $3.13 to $106.00, MBRX sits at the 4.6% percentile with a 14-day RSI of 45.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.91 to $8.89).
MBRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MBRX stock moving today?
Why MBRX Stock dropped -9.40% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
MBRX — Moleculin Biotech Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:04Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MBRX scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are the cash engine and the two flow-based pillars, each scoring 25% or less of its maximum. For a prospective investor, this profile points to a company that is not currently generating cash from operations, with negative returns on invested capital and no free-cash-flow yield to support valuation. The balance sheet metrics sit in a middling range rather than a distressed one, but the rating framework weights the absence of operating cash generation heavily. Upside would depend on factors outside the reported operating figures, and the source data does not establish a path to earnings or cash-flow inflection. This is an analytical reading of the rating, not a recommendation.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-25.1M | $33.6M | N/A | $-22.7M | $8.9M | N/A |
| FY 2024 | $0.0M | $-26.6M | $26.0M | N/A | $-23.9M | $4.3M | N/A |
| FY 2023 | $0.0M | $-29.6M | $29.8M | N/A | $-23.6M | N/A | N/A |
Per the SEC financials, operating losses narrowed from $-29.6M in FY 2023 to $-25.1M in FY 2025, while reported net income was positive in each period ($29.8M, $26.0M, $33.6M), a divergence from operating results that the source data does not explain. Gross, operating, and net margins are each 0% per the market data section, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash rose from $4.3M to $8.9M over the period, while free cash flow remained negative in every year presented.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, six items were published within roughly the prior 15 hours and are all tagged YELLOW under the impact label MARKET WIRE. The headlines reference a 1-for-20 reverse stock split announced amid a market selloff (per GuruFocus) and a separate reverse split announcement (per GlobeNewswire), as well as a Stock Titan item noting that half of the CFO's stock awards vest on grant. Several other items are generic quote or profile pages from Yahoo Finance, CNN, and Yahoo Finance Canada. Risk watch items include the reverse split activity and the sharp gap between the 52-week low of $3.13 and high of $106, which the source data does not reconcile. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE with no butterfly links and no proprietary signals.
Open Questions
- What is the source of reported net income of $33.6M in FY 2025 given operating losses of $-25.1M and zero revenue?
- What products, clinical programs, or revenue arrangements underlie the company, and what is its pipeline status?
- What do the reverse stock split announcements imply for share count, listing compliance, and dilution?
- Why does the 52-week range span from $3.13 to $106, and which price history is correct?
- What is the company's current debt position, since debt is reported as N/A in every period?
MBRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Moleculin Biotech Inc. (MBRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 19h ago
Moleculin Biotech, Inc. (MBRX) stock price, news, quote and history Yahoo Finance UK report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE CNN • 22h ago
symbol__ Stock Quote Price and Forecast CNN report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Moleculin Biotech (MBRX) Announces 1-for-20 Reverse Stock Split Amid Market Selloff GuruFocus report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Moleculin Announces Reverse Stock Split GlobeNewswire report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Half of the CFO's stock awards vest on grant at Moleculin Biotech (MBRX). Stock Titan report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Half of a 250,000-option grant vests on the grant date at Moleculin Biotech (MBRX). Stock Titan report covering Moleculin Biotech Inc. (MBRX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 3d ago
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A p
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MBRX Bull vs. Bear Conversation Board — What's Your Call at $7.90?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBRX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $7.67 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is MBRX (E • RQD 34/100) a Buy at $8.72?
Welcome to the MBRX (Moleculin Biotech Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $7.32 (-16.1%)
Spot @ $8.72 Pump the brakes on MBRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MBRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Moleculin Biotech Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $10.38 (+19.0%)
Spot @ $8.72 MBRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MBRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.72 (52-wk range $3.13 - $106.00), any beat on forward guidance forces shorts and underweight funds to chase.